NeuroOne® Investor Call Replay Available Through April 11th

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that a telephone replay of its investor conference call discussing recent disclosures, held yesterday, will be available through April 11, 2022. The webcast replay will be available for one year.

During the investor call, NeuroOne CEO Dave Rosa was joined by Dr. William Wustenberg, a biocompatibility expert that has worked with over 1500 companies over the past 25 years to provide guidance on biocompatibility testing required for a variety of FDA submissions. Mr. Rosa provided clarification regarding the disclosure included in the Company`s Form 8-K filed March 25, 2022 about its 510(k) clearance request to the FDA for its Evo® sEEG Electrode for less than 30-day use while Mr. Rosa and Dr. Wustenberg also answered questions submitted by the public. The device has already been 510(k) cleared for temporary (less than 24 hours) use.